Lots of interesting abstracts and cases were submitted for TCTAP 2023. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge and interact with authors as well as virtual participants by sharing your opinion in the comment section!
TCTAP A-021
Safety and Efficacy of Ticagrelor or Clopidogrel in East Asian Patients With Acute Coronary Syndrome and Diabetes Mellitus
By Yeonwoo Choi, Hoyun Kim, Jinho Lee, Do-Yoon Kang, Jung-Min Ahn, Duk-Woo Park, Seung-Jung Park
Presenter
Yeonwoo Choi
Authors
Yeonwoo Choi1, Hoyun Kim2, Jinho Lee3, Do-Yoon Kang4, Jung-Min Ahn4, Duk-Woo Park4, Seung-Jung Park4
Affiliation
Changwon Hanmaeum Hospital, Korea (Republic of)1, Sejong Hospital, Korea (Republic of)2, Kyung Hee University Medical Center, Korea (Republic of)3, Asan Medical Center, Korea (Republic of)4
View Study Report
TCTAP A-021
Acute Coronary Syndromes (STEMI, NSTE-ACS)
Safety and Efficacy of Ticagrelor or Clopidogrel in East Asian Patients With Acute Coronary Syndrome and Diabetes Mellitus
Yeonwoo Choi1, Hoyun Kim2, Jinho Lee3, Do-Yoon Kang4, Jung-Min Ahn4, Duk-Woo Park4, Seung-Jung Park4
Changwon Hanmaeum Hospital, Korea (Republic of)1, Sejong Hospital, Korea (Republic of)2, Kyung Hee University Medical Center, Korea (Republic of)3, Asan Medical Center, Korea (Republic of)4
Background
It is still unknown whether diabetes mellitus (DM) affects the relative safety and efficacy of ticagrelor and clopidogrel in East Asian patients with ACS. We investigated the safety and efficacy of ticagrelor versus clopidogrel according to the diabetic status of patients with acute coronary syndrome (ACS) intended for invasive management.
Methods
This prespecified analysis of the TICAKOREA (Ticagrelor Versus Clopidogrel in Asian/Korean Patients with ACS Intended for Invasive Management) trial included 800 Korean patients hospitalized for ACS randomized to ticagrelor or clopidogrel. The primary safety end point was clinically significant bleeding (PLATO major or minor bleeding) at 12 months; the efficacy end point was a major adverse cardiovascular event (MACE; a composite of cardiovascular death, myocardial infarction, or stroke).
Results
Of 800 patients, 216 (27.0%) had DM. The incidence of primary safety end point within 12 months was higher with ticagrelor than clopidogrel in patients with DM (13.8% vs. 8.0%; hazard ratio [HR], 1.87; 95% confidence interval [CI], 0.54-4.36) and in those without DM (10.2% vs. 4.3%; HR 2.45; 95% CI, 1.27-4.70); there was no significant interaction between treatment arm and diabetic status (P-for-interaction = 0.64). The incidence of MACE within 12 months also tended to be higher with ticagrelor than with clopidogrel in patients with DM (10.8% vs. 6.0%; HR, 1.90; 95% CI, 0.71-5.07) and in those without DM (8.5% vs. 5.7%; HR 1.51; 95% CI, 0.81-2.81) without any significant interaction between treatment arm and diabetic status (P-for-interaction = 0.71).
Conclusion
In Korean ACS patients undergoing early invasive management, diabetes status did not affect the relative safety and efficacy of ticagrelor and clopidogrel.